Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Mar 29, 2024 12:42pm
93 Views
Post# 35960215

RE:RE:RE:RE:RE:RE:Merck USA (MSD) acquires Phase 2 biotech for US$ 10.8 Bln.

RE:RE:RE:RE:RE:RE:Merck USA (MSD) acquires Phase 2 biotech for US$ 10.8 Bln.
Furthermore the PRA035 study measured clinical remisiion (and not 'cure"). Tthe PRA035 Artemis study demonstrated a 26.5% 'clinical remission, however clinical remission is a subjective reporting parameter that does not necessarily represent a "curative" response, as outline in the attached link

Clinical remission. This is something you can identify on your own. It simply means that you don’t have any noticeable symptoms. 


There are several types of remission. And “remission” tends to mean something different to patients than to their doctors, says Ariela Holmer, MD, a gastroenterologist with the NYU Langone Inflammatory Bowel Disease Center.

“Patients focus on symptoms, because those are what cause decreased quality of life and disability and why they come to see us in the first place," she says.

But to doctors, remission means that your small and large intestines are healthy so you can avoid complications, she says. There can be a disconnect between symptoms and what’s going on in your digestive tract.

<< Previous
Bullboard Posts
Next >>